{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T10:41:51Z","timestamp":1787222511943,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1038\/s41401-021-00832-z","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T04:04:10Z","timestamp":1643774650000},"page":"1210-1214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["NASH: regulatory considerations for clinical drug development and U.S. FDA approval"],"prefix":"10.1038","volume":"43","author":[{"given":"Brian E.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"832_CR1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","volume":"53","author":"V Ratziua","year":"2010","unstructured":"Ratziua V, Bellentanib S, Cortez-Pintoc H, Dayd C, Marchesinie G. A position statement on NAFLD\/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372\u201384. http:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(10)00414-9\/fulltext.","journal-title":"J Hepatol"},{"key":"832_CR2","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/hep.21327\/abstract;jsessionid=05BED8DE29EA91ADB17E9A321FEB71FC.f04t01","volume":"44","author":"M Ekstedt","year":"2006","unstructured":"Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865\u201373. https:\/\/doi.org\/10.1002\/hep.21327\/abstract;jsessionid=05BED8DE29EA91ADB17E9A321FEB71FC.f04t01.","journal-title":"Hepatology"},{"key":"832_CR3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJMra0912063","volume":"363","author":"G Targher","year":"2010","unstructured":"Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363:1341\u201350. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20879883.","journal-title":"N Engl J Med"},{"key":"832_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-020-00097-1","volume":"6","author":"S Tomah","year":"2020","unstructured":"Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol. 2020;6:9 https:\/\/doi.org\/10.1186\/s40842-020-00097-1.","journal-title":"Clin Diabetes Endocrinol"},{"key":"832_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328\u201357. https:\/\/doi.org\/10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"832_CR6","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","volume":"377","author":"AM Diehl","year":"2017","unstructured":"Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063\u201372. http:\/\/www.nejm.org\/doi\/abstract\/10.1056\/NEJMra1503519","journal-title":"N Engl J Med"},{"key":"832_CR7","unstructured":"U.S. Food & Drug Administration: News & Events. http:\/\/www.fda.gov\/news-events\/."},{"key":"832_CR8","unstructured":"FDA Guidance Drug-Induced Liver Injury: Premarketing Clinical Evaluation July 2009. https:\/\/www.fda.gov\/media\/116737\/download."},{"key":"832_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/hep.24376","volume":"54","author":"A Sanyal","year":"2011","unstructured":"Sanyal A, Brunt EM, Kleiner DE, Kowdley K, Chalasani N, Lavine J, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344\u201353. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4014460\/.","journal-title":"Hepatology"},{"key":"832_CR10","unstructured":"Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry (December 2018) Draft Guidance. https:\/\/www.fda.gov\/media\/119044\/download."},{"key":"832_CR11","unstructured":"Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry (June 2019) Draft Guidance https:\/\/www.fda.gov\/media\/127738\/download."},{"key":"832_CR12","unstructured":"Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) NCT02548351. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02548351."},{"key":"832_CR13","doi-asserted-by":"publisher","first-page":"105803","DOI":"10.1016\/j.cct.2019.06.017","volume":"84","author":"V Ratziu","year":"2019","unstructured":"Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, et al. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. Contemp Clin Trials. 2019;84:105803 https:\/\/doi.org\/10.1016\/j.cct.2019.06.017.","journal-title":"Contemp Clin Trials"},{"key":"832_CR14","unstructured":"Intercept Pharmaceuticals, Inc. Press Release June 29, 2020. https:\/\/ir.interceptpharma.com\/news-releases\/news-release-details\/intercept-receives-complete-response-letter-fda-obeticholic-acid"},{"key":"832_CR15","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/hep.31687","volume":"73","author":"FA Anania","year":"2020","unstructured":"Anania FA, Dimick-Santos L, Mehta R, Toerner J, Beitz J. Nonalcoholic steatohepatitis: current thinking from the division of hepatology and nutrition at the food and drug administration. Hepatology. 2020;73:2023\u20137. https:\/\/doi.org\/10.1002\/hep.31687.","journal-title":"Hepatology"},{"key":"832_CR16","unstructured":"Regulatory Perspectives for Development of Drugs for Treatment of NASH - 01\/29\/2021 - 01\/29\/2021 | FDA. www.fda.gov\/drugs\/news."},{"key":"832_CR17","unstructured":"Guidance for Industry Diabetes Mellitus \u2014 Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes (December 2008). https:\/\/www.fda.gov\/media\/71297\/download"},{"key":"832_CR18","unstructured":"Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry (March 2020). (https:\/\/www.fda.gov\/media\/135936\/download."},{"key":"832_CR19","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12916-020-01792-7","volume":"18","author":"PE Penson","year":"2020","unstructured":"Penson PE, Pirro M, Banach M. LDL-C: lower is better for longer\u2014even at low risk. BMC Med. 2020;18:320\u20135. https:\/\/doi.org\/10.1186\/s12916-020-01792-7.","journal-title":"BMC Med"},{"key":"832_CR20","unstructured":"Reorganization of the Office of New Drugs with Corresponding Changes to the Office of Translational Sciences and the Office of Pharmaceutical Quality https:\/\/www.fda.gov\/drugs\/regulatory-science-research-and-education\/reorganization-office-new-drugs-corresponding-changes-office-translational-sciences-and-office."},{"key":"832_CR21","unstructured":"Office of Immunology and Inflammation - Division of Hepatology and Nutrition (DHN). https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/office-immunology-and-inflammation-division-hepatology-and-nutrition-dhn."},{"key":"832_CR22","unstructured":"Division of Cardiology and Nephrology. https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/office-cardiology-hematology-endocrinology-and-nephrology-ochen-division-cardiology-and-nephrology."},{"key":"832_CR23","unstructured":"Division of Diabetes, Lipid Disorders, and Obesity. https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/office-cardiology-hematology-endocrinology-and-nephrology-division-diabetes-lipid-disorders-and."},{"key":"832_CR24","unstructured":"JARDIANCE\u00ae (empagliflozin tablets) Label Revision August 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/204629s026lbl.org."},{"key":"832_CR25","unstructured":"FDA Jardiance Supplement Approval Letter (August 18, 2021) Norman Stockbridge. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/204629Orig1s026ltr.pdf."},{"key":"832_CR26","unstructured":"Patient-focused drug development (PFDD). https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/cder-patient-focused-drug-development."},{"key":"832_CR27","unstructured":"U.S. Preventive Services Task Force https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/."},{"key":"832_CR28","doi-asserted-by":"crossref","unstructured":"Screening for Prediabetes and Type 2 Diabetes US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326:736\u201343. https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2783414.","DOI":"10.1001\/jama.2021.12531"},{"key":"832_CR29","unstructured":"Screening for Prediabetes and Type 2 Diabetes August 24, 2021. https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/screening-for-prediabetes-and-type-2-diabetes."},{"key":"832_CR30","unstructured":"Global Liver Institute. https:\/\/www.globalliver.org\/about."},{"key":"832_CR31","unstructured":"USPSTF Must Include Link to Liver Disease in Recommendation on Screening for Diabetes. https:\/\/www.globalliver.org\/news\/2021\/04\/uspstf-must-include-link-to-liver-disease-in-recommendation-on-screening-for-diabetes."},{"key":"832_CR32","unstructured":"Letter To USPSTF April 9, 2021. https:\/\/static1.squarespace.com\/static\/53bafd3ce4b0ae714af7153f\/t\/60759994a5a7834044a70c8b\/1618319765042\/Response+to+USPSTF+RE_+Diabetes+and+Prediabetes+Screening.pdf."},{"key":"832_CR33","unstructured":"Patient-Driven Transformation is Key to NASH Clinical Trials August 25, 2021. https:\/\/www.globalliver.org\/news\/2021\/nash-news-august."}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00832-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00832-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00832-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T05:08:46Z","timestamp":1651468126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00832-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00832-z","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"1 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}